The goal of this observational study is to learn if and how pharmacological and psychotherapeutic group treatments can treat clinical symptoms of children and adolescent patients with ADHD.
The main questions it aims to answer are:
* Are pharmacological and psychotherapeutic treatments effective on the clinical symptoms of patients with ADHD?
* Are pharmacological and psychotherapeutic treatments effective on symptoms of emotion-behavioral dysregulation?
* Is it possible to find associations between individual characteristics and treatment responses evaluating behavioral and neural correlates in children and adolescents with traits of emotion-behavioral dysregulation, externalizing disorders, and/or ADHD, using a panel of multimodal measures. May the data collected contribute to the definition of profiles useful for generating predictive hypotheses aimed at developing more personalized interventions?
Researchers will compare the data collected from patients treated with pharmacological and psychotherapeutic group treatments with the data of subjects of comparable sex/gender, age, diagnoses, on the waiting list for treatment to see if pharmacological and psychotherapeutic treatments effects ADHD and emotional dysregulation symprtoms.
Participants, patients who are offered treatment by clinicians according to standard clinical practice, will be asked to participate in the study by undergoing experimental assessments before and after the treatment.
The multimodal panel of proposed assessments includes:
* behavioral assessments, conducted through the completion of clinical and socio-demographic questionnaires;
* neuropsychological assessments, conducted through standardized computerized neuropsychological tests;
* neurophysiological assessments, conducted through the recording of NIRS (near infrared spectroscopy) and EEG (electroencephalogram) signals during an attentional task (Go-NoGo) and via a smartwatch.

开始日期2025-09-19

申办/合作机构-

CTR20251059

/ CompletedN/A

评估盐酸右哌甲酯片在健康成年受试者餐后状态下的单中心、随机、开放、单剂量、两周期、两序列、交叉生物等效性研究

主要研究目的：研究餐后状态下单次口服受试制剂盐酸右哌甲酯片（规格：2.5mg，河南中帅药业有限公司生产）与参比制剂盐酸右哌甲酯片（Focalin®，规格：2.5mg，Mikart, LLC生产）在健康成年受试者体内的药代动力学参数，评价餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂盐酸右哌甲酯片（规格：2.5mg）和参比制剂盐酸右哌甲酯片（Focalin®，规格：2.5mg）在健康成年受试者中的安全性。

开始日期2025-04-07

申办/合作机构

河南中帅药业有限公司

100 项与盐酸右哌甲酯相关的临床结果

登录后查看更多信息

100 项与盐酸右哌甲酯相关的转化医学

登录后查看更多信息

100 项与盐酸右哌甲酯相关的专利（医药）

登录后查看更多信息

295

项与盐酸右哌甲酯相关的文献（医药）

2025-12-01·Clinical Drug Investigation

Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults

Article

作者: Schneider-Pérez, Alex ; Forcadell Ferré, Marta ; Bouhajib, Mohammed ; Ramos-Quiroga, Josep Antoni

BACKGROUND:

Various oral methylphenidate formulations are available to treat attention-deficit/hyperactivity disorder, but unmet needs still exist, particularly for individuals with swallowing difficulties or those requiring more flexible dosing options. Two phase 1 studies evaluated the comparative bioavailability and safety/tolerability of two prolonged-release (PR) methylphenidate formulations, an oral suspension and a chewable tablet, compared with an established immediate-release (IR) oral tablet formulation.

METHODS:

Healthy volunteers were randomised to receive a single dose of methylphenidate PR oral suspension (total dose 60 mg; study 1) or chewable tablet (total dose 40 mg; study 2) and methylphenidate IR tablets (total dose 60 mg in study 1 and 40 mg in study 2) in a crossover manner, with a 7-day washout between treatment periods. Blood samples were collected over the 24-h post-administration period. Comparative bioavailability was defined as the 90% confidence interval (CI) of the relative mean plasma D-methylphenidate area under the plasma concentration-time curve from zero to last measurable concentration (AUC_last) of methylphenidate PR formulation to methylphenidate IR being between 80 and 125%. Adverse events (AEs) were documented.

RESULTS:

In total, 24 individuals (mean age 39-42 years, approximately 50% male) were randomised in each study, of whom 23 received methylphenidate PR oral suspension in study 1 and 23 received methylphenidate PR chewable tablets in study 2; 24 received methylphenidate IR tablets in each study. The relative mean plasma D-methylphenidate AUC_last ratios for methylphenidate PR formulation to methylphenidate IR tablets had 90% CIs of 82.30-87.18% in study 1 and 90.01-97.52% in study 2. Treatment-emergent AEs were reported in 26% and 22% of participants receiving the oral suspension and chewable tablets, respectively (versus 50% and 33% of those receiving the IR tablets in the respective studies). These AEs were typical of orally administered methylphenidate, mild in severity and, in general, resolved prior to study end.

CONCLUSIONS:

The methylphenidate PR oral suspension and chewable tablet formulations are bioequivalent in terms of the total extent of exposure (AUC_last) to methylphenidate IR tablets and are tolerable in healthy adults.

2025-10-18·Future Medicinal Chemistry

Consecutive double chiral-switches strategy. ADHD methylphenidate drugs: from two racemates via racemate to enantiomer

Article

作者: Agranat, Israel ; D’Acquarica, Ilaria

The Perspective presents the strategy of double chiral switches of drugs, illustrating the scenario of consecutive double chiral switches of methylphenidate. The two chirality centers of methylphenidate hydrochloride give rise to four stereoisomers grouped into two racemates, two enantiomer pairs: [(αR,2S)/(αS,2R)] (racemate a) and [(αR,2R)/(αS,2S)] (racemate b). A detailed analysis of the development, drug-regulatory approvals and the corresponding patents and trademarks of methylphenidate drugs indicated the following double chiral switches: (±)-[(αR,2R)/(αS,2S)]-methylphenidate HCl + (±)-[(αR,2S)/(αS,2R)]-methylphenidate HCl (Centedrin)→(±)-[(αR,2R)/(αS,2S)]-methylphenidate HCl (Ritalin)→(+)-(αR,2R)-methylphenidate HCl (Focalin). The analysis showed that the Food and Drug Administration approval of Ritalin in 1955 represented the first chiral switch of the mixture of two racemates to the single racemate b. In 2001, Ritalin underwent a second chiral switch to the single-enantiomer Focalin. Ritalin and Focalin developed into successful Attention-Deficit/Hyperactivity Disorder (ADHD) drugs. Notably, the single-enantiomer drug Focalin has not driven away the racemate Ritalin from ADHD markets. The notations of the active ingredients of Ritalin (methylphenidate hydrochloride) and of Focalin (dexmethylphenidate hydrochloride) are stereochemically flawed and the designations of the stereodescriptors of relative configurations erythro and threo are obsolete. The Perspective calls for correct notations of methylphenidate drugs and for future applications of the double chiral-switches strategy.

2025-10-13·EXPERT OPINION ON PHARMACOTHERAPY

Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials

Review

作者: Bilgic, Ayhan ; Ferahkaya, Hurşit

INTRODUCTION:

Stimulant medications, such as methylphenidate and amphetamine derivatives, and non-stimulant medications, such as atomoxetine, guanfacine, clonidine, and viloxazine, are considered the cornerstones of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD). However, a significant number of individuals respond partially to these treatments or are concerned about side effects. This creates a need for new treatment strategies that target alternative neurobiological mechanisms and offer improved tolerability and efficacy profiles.

AREA COVERED:

This review examines pharmacological agents currently in phase III clinical development or recently completed trials for the treatment of ADHD. We highlight four promising candidates: centanafadine, solriamfetol, CTx-1301, and NRCT-101SR. We discuss their pharmacological mechanisms, clinical efficacy, safety profiles, and regulatory status, with an emphasis on how these agents may address existing therapeutic gaps and the potential clinical implications. A literature search was conducted using PubMed and ClinicalTrials.gov databases for articles published between January 2018-July 2025.

EXPERT OPINION:

Recent advances in ADHD pharmacotherapy suggest that approaches targeting monoaminergic systems beyond dopamine and noradrenaline reuptake inhibition may provide therapeutic benefits. Additionally, multi-phase extended-release formulations may improve adherence and enhance symptom control throughout the day. As phase III data become available, these agents have the potential to redefine ADHD treatment paradigms.

159

项与盐酸右哌甲酯相关的新闻（医药）

2026-02-24

·求实药社

告别一药难求！多款国产ADHD药物密集上市，终结进口药“一家独大”时代

在中国，注意缺陷多动障碍（ADHD）患者群体规模已超3400万人。长期以来这个群体的临床治疗高度依赖进口药物。随着立方制药首仿药破冰上市，祐儿医药改良型新药多剂型获批落地，以及爱科百发创新复方制剂的顺利获批，已有多款国产ADHD治疗药物上市，依赖进口药的局面正逐步被打破。 ADHD赛道，一场国产替代与升级的破局之战已正式拉开序幕。 01 市场潜力待释放注意缺陷多动障碍（ADHD）是一种常见的慢性神经发育障碍，特征为与发育水平不相称的注意缺陷、多动冲动，具体表现为注意力不集中、冲动任性、活动过多、学习困难等。根据《注意缺陷多动障碍早期识别、规范诊断和治疗的儿科专家共识（2020年）》，我国儿童和青少年ADHD患病率约为6.26%，约2300万人，但临床就诊率却仅约10%。数据显示，高达65%的ADHD儿童在成年后仍会残留相关症状，严重影响患者的学习工作效率、社交功能及心理健康。从国内患病情况来看，ADHD的患病率呈稳步上升趋势。截至2024年，中国ADHD患者总数约为3400万名，其中45%为6-17岁的儿童及青少年群体。预计未来十年，该患者群体将以1.3%的复合年增长率持续增长，到2035年突破3920万名，庞大的患者基数为治疗药物市场提供了广阔的增长空间。目前，由于公众对ADHD疾病的认知不足，叠加临床可用药物种类有限，2024年中国ADHD治疗药物市场规模为11亿元。不过，随着社会对精神健康领域的关注度持续提升，加之更多创新药物获批上市、诊疗规范化水平不断提高，国内ADHD药物市场有望进入快速增长通道。根据行业预测，到2035年，中国ADHD治疗药物市场规模将达到131亿元，2024年至2035年的复合年增长率高达24.9%，成为医药行业中具有潜力的细分赛道。图片来源：爱科百发招股书 02 国产药物破局目前，ADHD治疗主要依靠药物与非药物结合方式。其中，药物治疗包括兴奋剂（作用于多巴胺受体，起效快）和非兴奋剂（作用于去甲肾上腺素，起效较慢）。兴奋剂疗效较好，但存在作用时间短、潜在滥用风险等问题。盐酸哌甲酯缓释片是一种中枢神经兴奋剂，属于一类精神药品，主要通过作用于多巴胺系统来快速改善注意力缺陷、多动症状，被全球多个国家的ADHD防治指南列为一线治疗药物。盐酸哌甲酯缓释片由原研企业杨森公司开发，2000年获得美国FDA批准上市；2005年进入中国市场，商品名为专注达，初始适应症聚焦儿童ADHD，随后获批扩展至青少年及成人适应症，成为国内ADHD治疗领域的“金标准”药物之一。得益于国内ADHD诊断率的提升，以及患者用药需求的释放，盐酸哌甲酯缓释片在国内市场的需求呈现持续快速增长的态势。药智数据显示，2024年该品种国内公立医疗机构销售额已超过5亿元人民币，预计2025年进一步攀升至约5.5亿元人民币。盐酸哌甲酯缓释片国内公立医疗机构销售额图片来源：药智数据长期以来，国内盐酸哌甲酯缓释片市场始终由原研药独占，直到2025年4月，立方制药的盐酸哌甲酯缓释片正式获批上市，才打破了进口药品的垄断格局，成为该品种国内首款获批的国产制剂。在其他剂型上，2024年1月，祐儿医药与Tris Pharma公司合作开发的盐酸哌甲酯口服缓释干混悬剂成功获批上市，适应症为注意缺陷多动障碍。此前，双方合作开发的盐酸哌甲酯缓释咀嚼片已于2023年12月获批上市，并于2024年11月实现全国正式供药。盐酸哌甲酯口服缓释干混悬剂和盐酸哌甲酯缓释咀嚼片是Tris公司开发的改良型新药，分别于2012年和2015年在美国获批上市。一项临床研究数据显示，这两款药物均能在服药后45分钟至12小时内显著改善ADHD患者的症状。 2025年1月，中帅药业的盐酸右哌甲酯缓释胶囊也成功获批上市，成为该品种的首仿产品。据悉，盐酸右哌甲酯作为盐酸哌甲酯的右旋异构体，该胶囊采用口服小丸药物吸收技术，包含50%速释微丸和50%迟释微丸。该品种于2005年5月在美国获批上市，适用于六岁及以上注意缺陷与多动障碍患者的治疗。 2026年1月，爱科百发的复方氯丝右哌甲酯胶囊（爱智达）在中国获批，适用于6岁及6岁以上注意缺陷多动障碍患者的治疗。复方氯丝右哌甲酯胶囊是一款具有创新机制的ADHD治疗药物，是全球首款且目前唯一包含速释右哌甲酯（d-MPH）和前药丝右哌甲酯（SDX）的复方制剂。该药物于2021年3月在美国获批，是近二十年来首个获得美国FDA批准的新一代哌甲酯类药物。2021年12月，爱科百发从Commave引进复方氯丝右哌甲酯胶囊的许可。速释右哌甲酯是一种速释药物，在全球用于治疗ADHD已超过20年，可在30分钟内快速起效，满足患者对核心症状的即时控制需求。前药丝右哌甲酯是一种前药，在体内缓慢转化为d-MPH，在一天活动时间内充分改善ADHD症状，降低传统哌甲酯类缓释药物因d-MPH浓度晚间骤降引发的症状反弹（或崩溃）风险。相较于传统单药缓释制剂，复方氯丝右哌甲酯胶囊的双相释放药代动力学特征更贴合ADHD患者“晨间起床-白天工作学习社交-晚间课外作业/工作-入睡”的生理节律与生活场景。这种创新设计使其不仅适合6岁及以上的学龄儿童和青少年，同样也适合成人的ADHD患者，同时可以减少多次服药带来的依从性和影响睡眠的问题。盐酸托莫西汀是一种选择性去甲肾上腺素再摄取抑制剂，可用于一线治疗儿童和青少年多动症，该药物由礼来公司原研开发。目前，盐酸托莫西汀在国内的国产化进程已较为成熟，国内已有数十家生产企业获批生产该品种，包括华海药业、济川药业、山东新时代等药企，剂型覆盖了口服溶液、胶囊剂和片剂等多种形式，能够满足不同患者的用药需求，有效提升了该类药物的临床可及性。 03 破解供应困局在全球范围内，中枢精神兴奋剂因其显著的疗效，成为多数国家治疗ADHD的首选药物，但由于该类药物具有潜在的滥用风险，其生产、流通、使用全流程均被纳入严格的管控体系，国内也不例外。例如，强生旗下的盐酸哌甲酯缓释片（专注达），属于国家严格管制的第一类精神药品，生产和流通受到极其严格的监管，需凭专业医师开具的“红处方”才能购买，只有通过毒麻药品管理考核的主治医师及以上级别医生先对患者进行详细的临床评估，明确诊断为ADHD后，方可考虑开具类似药物。 2024年7月，强生旗下西安杨森公司对外发布说明，专注达属于国家管控的一类精神药品，生产所需的主要原材料受全球管制。自2023年以来，受全球ADHD诊断率提升、患者用药需求激增等多重因素影响，专注达的全球需求量持续大幅增长，尽管公司已计划在2024年全年全力保障该药供应，但全球需求量仍超出了公司的产能上限，导致供应紧张局面难以快速缓解。为了尽可能缓解国内市场的供应压力，西安杨森彼时明确表示，计划将中国市场专注达的包装工序从海外工厂转移至西安本地工厂，通过优化供应链布局，加快中国市场的药品供应速度。在近20年的时间里，强生的专注达之所以能够长期垄断国内盐酸哌甲酯缓释片市场，主要原因在于该药采用了复杂的渗透泵技术结构及工艺。该技术能够实现药物在体内长达24小时的持续、平稳释放，不仅显著提升了药物的治疗效果，还能有效减少药物浓度波动带来的副作用，大幅提升患者的用药安全性与依从性。渗透泵技术的高壁垒，使得国内企业长期难以突破，这也导致了专注达长期一家独大的市场格局。近年来，近年来中国高度重视精神健康领域的发展，尤其聚焦儿科药物的创新与可及性提升，一系列支持政策的密集出台，为ADHD药物的国产化研发与上市开辟了绿色通道。2017年，ADHD药物被纳入《第二批鼓励研发申报儿童药品清单》，为相关仿制药与创新药开辟了审批绿色通道，加快了上市进程。《中国儿童发展纲要（2021—2030年）》也明确提出鼓励儿科药物创新、简化流程等举措。这些政策支持不仅降低了ADHD药物的研发与上市成本，也提升了企业参与该领域的积极性，为市场增长注入了政策红利。立方制药盐酸哌甲酯缓释片、中帅药业盐酸右哌甲酯缓释胶囊等仿制药相继获批，祐儿医药的改良型新药盐酸哌甲酯缓释咀嚼片、口服缓释干混悬剂实现全国供药，爱科百发的创新复方制剂顺利上市，多款国产多动症药物获批，不仅打破了原研药长期垄断的市场格局，也缓解了国内ADHD患者的用药短缺问题。 04 结语未来，随着国内药企研发实力的不断提升，围绕ADHD治疗的剂型创新、靶点创新、联合用药方案创新等取得突破，国内患者的用药可及性将大幅提升，同时国产药物的性价比优势也将降低患者的用药负担，进一步推动国内ADHD诊疗领域的规范化发展。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们国内规模最大的干细胞及类器官领域盛会！ ISO 2026 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

上市批准

2026-02-17

·BioSpace

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”). “This long-term financing from life science–focused institutional investors represents strong validation of our strategy, our technology, and the significant commercial opportunity ahead. The transaction included insider participation underscoring our confidence in the value we are building and our commitment to standing shoulder-to-shoulder with our shareholders,” said Cingulate CEO Shane J. Schaffer. “The at-the-market pricing, six-month investor lock-up, and 80% warrant coverage reflect a well-structured transaction and compare favorably with current market conditions.” The PIPE was completed at the closing price of $5.04 per share on January 26, 2026 with 80% warrant coverage. All investors participating in the PIPE financing have agreed to a 180-day lock-up period, further aligning long-term investor interests and reinforcing confidence in the Company’s execution through key upcoming milestones. The financing proceeds will support general operations as the company works toward a critical milestone—the commercial launch of CTx-1301, subject to FDA approval. In connection with the PIPE financing, Falcon Creek Capital received the right to designate up to two members of Cingulate’s board of directors, the first of which will be former Cingulate board member, Jeff Hargroves. Mr. Hargroves brings extensive pharmaceutical experience and a strong understanding of Cingulate’s strategic priorities and operations. Mr. Hargroves was also a significant participant in the PIPE financing. The securities were issued in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D and have not been registered under the Securities Act or applicable state securities laws. The Company has agreed to resale registration statement covering the shares issued and issuable in the transaction. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Transaction Summary PIPE Size: $12 million gross proceeds All investors in the PIPE financing are subject to a 180-day lock-up period pursuant to the definitive transaction documents Total Potential Proceeds: Up to $21.4 million Pricing: Nasdaq closing price on January 26, 2026 of $5.04 per share Preferred Stock: Convertible upon stockholder approval; accrues 12% annualized interest until conversion Warrants: Exercisable upon stockholder approval; three-year term. About ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental condition affecting approximately 20 million individuals in the United States, including 8 million children and 12 million adults. While stimulant medications remain the standard of care, existing extended-release products fail to provide consistent, entire active-day symptom control, often requiring multiple doses. About CTx-1301 CTx-1301 is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform to deliver three precisely timed releases of dexmethylphenidate across the day. The candidate is being evaluated under the FDA’s 505(b)(2) regulatory pathway for the treatment of ADHD. In October 2025, the FDA accepted Cingulate’s NDA for review and assigned a PDUFA target action date of May 31, 2026. NDA acceptance indicates that the submission is sufficiently complete for substantive review and does not imply approval or guarantee any specific outcome. About Cingulate Inc. Cingulate Inc. (NASDAQ: CING) is a biopharmaceutical company leveraging its proprietary Precision Timed Release™ (PTR™) platform to develop next-generation pharmaceutical products designed to improve outcomes in conditions marked by suboptimal therapeutic coverage and burdensome dosing schedules. The Company’s lead candidate, CTx-1301, is in commercial-stage development for ADHD, with additional pipeline programs targeting anxiety and other neuropsychiatric indications. Cingulate is headquartered in Kansas City, Kansas. About Falcon Creek Capital Falcon Creek Capital Advisor LLC is a specialized investment firm focused on public and private equity investments in the life sciences, healthcare, and technology sectors. The firm is known for its disciplined, long-term investment approach and for partnering with companies at pivotal inflection points, providing structured capital solutions that support commercialization, growth initiatives, and pipeline expansion. Falcon Creek Capital combines public market expertise with an active, collaborative approach to governance and strategic execution. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Specifically, these statements include, but are not limited to, statements regarding our expected cash runway, the potential approval and commercialization of CTx-1301, the potential PDUFA date of May 31, 2026, anticipated capital needs and financing plans, designation of Frederick Jiang as a board observer, and subject to stockholder approval, as a director, the long-term investment strategy of Falcon Creek and potential proceeds from the exercise of warrants. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025 and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. Investor & Media Relations: Thomas Dalton Vice President, Corporate and Government Relations, Cingulate tdalton@cingulate.com (480) 529-5434

申请上市

2026-02-14

·三弟药闻

20260214 中国国家药品监督管理局药品审评中心(CDE)受理信息--化药

1. 奥美拉唑肠溶胶囊受理号：JYHS2600003 企业名称：EUROPHARM LABORATOIRES CO LTD; JEAN-MARIE PHARMACAL CO. LTD.; U.Bon HealthTech Co., Ltd. 靶点与机制：质子泵抑制剂。奥美拉唑为苯并咪唑衍生物，是一种前体药。口服后在酸性环境中转化为活性形式，不可逆地与胃壁细胞H+/K+-ATP酶（质子泵）结合，抑制胃酸分泌的最终步骤。用于治疗胃食管反流病、消化性溃疡、卓-艾综合征等。注册与分类：进口上市申请，5.2类 (境外上市的非原研药申请进口)2. 非布司他降解产物Ⅰ对照品受理号：JTH2600036 企业名称：F.I.S.-Fabbrica Italiana Sintetici S.p.A.; TEIJIN PHARMA LIMITED; 安斯泰来制药(中国)有限公司靶点与机制：对照品。此为非布司他（一种黄嘌呤氧化酶抑制剂，用于治疗痛风）的特定降解杂质或代谢产物的标准品/对照品。用于药品质量研究，如有关物质检查、方法学验证等，确保药品安全有效。注册与分类：进口对照品申请(不适用常规注册分类)3. 盐酸丙卡特罗口服溶液受理号：CYHS2600493 企业名称：海南广升誉制药有限公司; 安徽永生堂药业有限责任公司靶点与机制：β2-肾上腺素受体激动剂。丙卡特罗选择性激动支气管平滑肌上的β2受体，激活腺苷酸环化酶，增加细胞内cAMP水平，从而松弛支气管平滑肌，缓解喘息症状。用于治疗支气管哮喘、慢性阻塞性肺疾病等引起的喘息症状。口服溶液剂型适用于儿童及吞咽困难者。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)4. 维U颠茄铝分散片受理号：CYHB2600366 企业名称：修正药业集团股份有限公司; 修正药业集团股份有限公司靶点与机制：复方抗酸解痉药。维生素U促进胃黏膜修复；颠茄提取物（含莨菪碱）为抗胆碱药，抑制胃酸分泌、缓解胃肠痉挛；氢氧化铝中和胃酸、保护胃黏膜。用于缓解胃酸过多、胃痉挛引起的胃痛、烧心等症状。注册与分类：补充申请，原5类 (针对按旧分类批准的上市药品提出的变更)5. 羧甲司坦口服溶液受理号：CYHB2600365 企业名称：成都倍特得诺药业有限公司; 成都倍特得诺药业有限公司靶点与机制：黏液溶解剂/祛痰药。羧甲司坦能使痰液中的黏蛋白二硫键断裂，降低痰液粘度，使其易于咳出。用于慢性支气管炎、支气管哮喘等疾病引起的痰液粘稠、咳痰困难。注册与分类：补充申请，3类 (针对已上市的仿制药提出的变更)6. 复方氨基酸注射液(18AA-V-SF) 受理号：CYHB2600364 企业名称：重庆药友制药有限责任公司; 重庆药友制药有限责任公司靶点与机制：肠外营养剂。本品为含有18种氨基酸的复方制剂，为机体提供合成蛋白质所需的氮源，用于改善手术前后患者的营养状况，或为不能经胃肠道摄取营养的患者提供氨基酸。注册与分类：补充申请(针对已上市药品提出的变更)7. 注射用TUL108 受理号：CXHL2600206 企业名称：珠海联邦制药股份有限公司靶点与机制：注射用TUL108是由公司自主设计并研发的一种新型超广谱β-内醯胺酶抑制剂，拟用于治疗由革兰氏阴性菌或革兰氏阳性菌所引起的感染，包括复杂性尿路感染(cUTI)、复杂性腹腔感染(cIAI)及肺部感染和血流感染。注册与分类：新药临床申请，1类 (创新药)8-10. NH601缓释胶囊受理号：CXHL2600205, CXHL2600204, CXHL2600203 企业名称：江苏恩华药业股份有限公司; 苏州恩华生物医药科技有限公司靶点与机制：推测是GABAA receptor激动剂注册与分类：新药临床申请，2.2类 (改良型新药-增加新适应症/改变给药途径，有临床优势)11-12. 布南色林片受理号：JYHZ2600044, JYHZ2600043 企业名称：Sumitomo Pharma Co., Ltd.; Sumitomo Pharma Co., Ltd. Suzuka Plant; 无靶点与机制：非典型抗精神病药/多巴胺D2和5-HT2A受体拮抗剂。布南色林对多巴胺D2受体和5-羟色胺5-HT2A受体均有高亲和力，通过平衡拮抗作用，在改善精神分裂症阳性、阴性症状的同时，可能减少锥体外系反应等副作用。注册与分类：进口再注册申请，5.1类 (已在中国上市的进口原研药申请延续注册)13. 注射用JX10 受理号：JXHB2600019 企业名称：Corxel Pharmaceuticals, Inc.; Fuji Yakuhin Co., Ltd 靶点与机制：JX10 是一款用于治疗急性缺血性脑卒中（AIS）的在研药物。该药物的作用机制包括溶栓和抗炎。JX10通过恢复急性脑卒中后的临界血流量，延长原本短暂的治疗窗口期，即发病后 4.5 小时内，使得更多患者可以从目前的标准治疗中获益。注册与分类：进口新药补充申请，1类 (针对在研创新药的变更申请)14. 非布司他对照品受理号：JTH2600035 企业名称：F.I.S. - Fabbrica Italiana Sintetici S.p.A.; TEIJIN PHARMA LIMITED; 安斯泰来制药(中国)有限公司靶点与机制：对照品。此为抗痛风药非布司他（黄嘌呤氧化酶抑制剂）的化学对照品，用于药品质量标准的建立和检验。注册与分类：进口对照品申请15. 盐酸丙嗪受理号：JTH2600034 企业名称：PCAS FINLAND OY; PCAS; 华益药业科技（安徽）有限公司靶点与机制：吩噻嗪类抗精神病药/多巴胺受体拮抗剂。盐酸丙嗪是丙嗪的盐酸盐，通过阻断中枢多巴胺受体发挥抗精神病作用。本次申报的应是原料药或对照品，用于药品生产或质量控制。注册与分类：进口原料药/对照品申请16. 布立西坦受理号：JTH2600033 企业名称：United States Pharmacopeial Convention 美国药典委员会; United States Pharmacopeial Convention 美国药典委员会; 浙江普洛康裕制药有限公司靶点与机制：新型抗癫痫药/SV2A配体。布立西坦通过与突触前膜的突触囊泡蛋白2A结合，可能调节神经递质释放，发挥抗癫痫作用。本次申报的应是原料药或对照品。注册与分类：进口原料药/对照品申请17. 碳酸镧咀嚼片受理号：CYHS2600492 企业名称：成都纵联医疗健康科技有限公司; 太极集团四川太极制药有限公司靶点与机制：磷酸盐结合剂。碳酸镧在肠道内与食物中的磷酸盐结合，形成不溶性的磷酸镧复合物，从而减少肠道对磷的吸收。用于控制慢性肾脏病透析患者的高磷血症。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)18-19. 复方氨基酸注射液(18AA-VII) 受理号：CYHS2600491, CYHS2600490 企业名称：湖北一半天制药有限公司; 湖北一半天制药有限公司靶点与机制：肠外营养剂。含有18种氨基酸的复方制剂，为机体提供合成蛋白质所需的必需和非必需氨基酸。不同亚型（如18AA-VII）的氨基酸组成和比例可能针对特定疾病状态（如肝病、肾病、创伤等）优化。用于不能经胃肠道摄取或摄取不足的患者的营养支持。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)20. 玻璃酸钠滴眼液受理号：CYHS2600489 企业名称：乐泰药业（海南）有限公司; 乐泰药业（海南）有限公司靶点与机制：保湿润滑剂。玻璃酸钠（透明质酸钠）是一种天然高分子粘多糖，具有极强的保水性和粘弹性。滴眼后能在眼表形成一层稳定的水化膜，润滑眼球表面，缓解干眼症引起的眼部干涩、疲劳等不适。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)21-22. 磷苯妥英钠注射用浓溶液受理号：CYHS2600488, CYHS2600486 企业名称：海南慧通生物医药科技有限公司; 山东北大高科华泰制药有限公司靶点与机制：前体药物/抗惊厥药。磷苯妥英是苯妥英的前体药物，在体内被磷酸酯酶迅速转换为苯妥英。苯妥英通过稳定神经细胞膜，抑制钠离子内流，减少神经元异常放电的扩散，从而控制癫痫发作。注射剂用于治疗癫痫持续状态和预防神经外科手术中的癫痫发作。注册与分类：仿制上市申请，3类 (仿制境内已上市的药品)23. 来那度胺胶囊受理号：CYHS2600483 企业名称：山东丹红制药有限公司; 杨凌步长制药有限公司靶点与机制：免疫调节剂。来那度胺是沙利度胺的衍生物，具有多种作用：1) 通过结合E3泛素连接酶复合物，促进Ikaros和Aiolos等转录因子降解，直接抑制肿瘤细胞；2) 刺激T细胞和NK细胞活性，增强免疫；3) 抑制血管生成。用于多发性骨髓瘤、骨髓增生异常综合征等。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)24-25. 盐酸右哌甲酯缓释胶囊受理号：CYHS2600482, CYHS2600481 企业名称：宜昌人福药业有限责任公司; 宜昌人福药业有限责任公司靶点与机制：中枢神经系统兴奋剂。右哌甲酯是哌甲酯的右旋异构体，通过阻断多巴胺和去甲肾上腺素转运体，增加突触间隙中这两种神经递质的浓度，从而改善注意力、控制冲动。缓释剂型可实现全天持续控制症状。用于治疗注意缺陷多动障碍。注册与分类：仿制上市申请，3类 (仿制境内已上市的药品)26. 钠钾镁钙注射用浓溶液受理号：CYHS2600480 企业名称：江西泰吉立生物医药科技有限公司; 浙江赛默制药有限公司靶点与机制：电解质补充剂。提供钠、钾、镁、钙四种阳离子，用于预防和纠正体内电解质（尤其是钾、镁、钙）的缺乏或失衡，常用于肠外营养或纠正术后电解质紊乱。注册与分类：仿制上市申请，3类 (仿制境内已上市的药品)27. 利奈唑胺片受理号：CYHS2600477 企业名称：湖南明瑞制药股份有限公司; 湖南明瑞制药股份有限公司靶点与机制：噁唑烷酮类抗生素/抑制细菌蛋白质合成。利奈唑胺与细菌核糖体50S亚基结合，抑制70S起始复合物的形成，从而在翻译的早期阶段阻止细菌蛋白质合成。对多重耐药的革兰氏阳性菌（如MRSA、VRE）有效。用于治疗敏感菌引起的复杂性皮肤软组织感染、社区获得性肺炎等。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)28. 枸橼酸西地那非口崩片受理号：CYHS2600476 企业名称：华泰民康(沈阳)科技有限公司; 苏州特瑞药业股份有限公司靶点与机制：5型磷酸二酯酶选择性抑制剂。西地那非通过选择性抑制阴茎海绵体内的PDE5，增强一氧化氮介导的血管舒张作用，增加血流量，促进勃起。口崩片在口腔内可迅速崩解，无需水送服，提高了用药便利性和患者依从性。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)29. 地西泮鼻喷雾剂受理号：CYHS2600475 企业名称：石药集团欧意药业有限公司; 石药集团欧意药业有限公司靶点与机制：苯二氮䓬类镇静催眠/抗惊厥药/GABA-A受体正向变构调节剂。地西泮与GABA-A受体上的苯二氮䓬位点结合，增强GABA介导的氯离子通道开放，产生中枢抑制作用。鼻喷雾剂型可快速通过鼻黏膜吸收，用于急性治疗癫痫丛集性发作或急性反复性惊厥，相比直肠给药更便捷、体面。注册与分类：仿制上市申请，4类 (仿制境内已上市的原研药)30. 枸橼酸氢钾钠颗粒受理号：CYHB2600363 企业名称：湖南九典制药股份有限公司; 湖南九典制药股份有限公司靶点与机制：尿碱化剂/尿酸和胱氨酸结石预防剂。通过提供碱性钾盐和钠盐，碱化尿液，增加尿酸和胱氨酸在尿液中的溶解度，防止其结晶形成结石。用于溶解尿酸结石和预防新结石的形成。注册与分类：补充申请，4类 (针对已上市的仿制药提出的变更)31. 左乙拉西坦缓释颗粒受理号：CYHB2600362 企业名称：神基（上海）制药有限公司; 江苏安必生制药有限公司靶点与机制：抗癫痫药/突触囊泡蛋白SV2A配体。左乙拉西坦的确切机制未完全阐明，但已知其主要通过与突触前膜的突触囊泡蛋白SV2A结合，调节神经递质的释放，从而抑制癫痫样放电。缓释颗粒剂型可实现更平稳的血药浓度，减少每日服药次数，提高依从性。注册与分类：补充申请，2.2类 (改良型新药-改变剂型，有临床优势)32. 利伐沙班片受理号：CYHB2600361 企业名称：南京海辰药业股份有限公司; 南京海辰药业股份有限公司靶点与机制：直接Xa因子抑制剂。利伐沙班直接、高选择性地抑制凝血因子Xa，阻断凝血瀑布的内源性和外源性途径，抑制凝血酶的产生和血栓形成。用于预防和治疗静脉血栓栓塞症，以及非瓣膜性房颤患者的卒中预防。注册与分类：补充申请(针对已上市药品提出的变更)33. 注射用头孢他啶阿维巴坦钠受理号：CYHB2600360 企业名称：正大天晴药业集团股份有限公司; 连云港润众制药有限公司靶点与机制：β-内酰胺类抗生素与β-内酰胺酶抑制剂复方。头孢他啶是第三代头孢菌素，通过抑制细菌细胞壁合成发挥杀菌作用。阿维巴坦是新型β-内酰胺酶抑制剂，可抑制Ambler分类的A类、C类和部分D类β-内酰胺酶（包括碳青霉烯酶），恢复头孢他啶对耐药菌的活性。用于治疗复杂腹腔感染、医院获得性肺炎等由多重耐药革兰氏阴性菌引起的感染。注册与分类：补充申请，4类 (针对已上市的仿制药提出的变更)34. 小儿氨酚黄那敏颗粒受理号：CYHB2600359 企业名称：扬子江药业集团广州海瑞药业有限公司; 扬子江药业集团广州海瑞药业有限公司靶点与机制：复方感冒药。对乙酰氨基酚（解热镇痛）；马来酸氯苯那敏（抗组胺，缓解流涕、打喷嚏）；人工牛黄（清热解毒、镇惊）。用于缓解儿童普通感冒及流行性感冒引起的发热、头痛、四肢酸痛、打喷嚏、流鼻涕、鼻塞等症状。注册与分类：补充申请(针对已上市药品提出的变更)35. 氢溴酸伏硫西汀片受理号：CYHB2600358 企业名称：成都康弘药业集团股份有限公司; 成都康弘药业集团股份有限公司靶点与机制：多模式抗抑郁药/5-HT再摄取抑制剂和5-HT受体调节剂。伏硫西汀是5-HT再摄取抑制剂，同时也是5-HT1A受体激动剂和5-HT3受体拮抗剂。这种多重作用机制可能共同起效，发挥抗抑郁和抗焦虑作用，用于治疗成人重度抑郁障碍。注册与分类：补充申请，4类 (针对已上市的仿制药提出的变更)36. 盐酸雷尼替丁胶囊受理号：CYHB2600357 企业名称：江西普丽尔药业有限公司; 江西普正制药股份有限公司靶点与机制：H2受体拮抗剂。雷尼替丁竞争性拮抗胃壁细胞上的组胺H2受体，抑制基础胃酸和刺激引起的胃酸分泌。用于治疗胃溃疡、十二指肠溃疡、反流性食管炎等。注册与分类：补充申请(针对已上市药品提出的变更)37-38. 替格瑞洛片受理号：CYHB2600356, CYHB2600355 企业名称：乐声药业石家庄有限公司; 南京海辰药业股份有限公司; 江苏利泰尔药业有限公司; 南京海辰药业股份有限公司靶点与机制：P2Y12 ADP受体拮抗剂。替格瑞洛是可逆性、直接作用的P2Y12 ADP受体拮抗剂，无需代谢激活，可快速、强效抑制血小板聚集。与氯吡格雷相比，起效更快，抗血小板作用更强，个体差异小。用于急性冠脉综合征患者预防心血管事件。注册与分类：补充申请，4类 (针对已上市的仿制药提出的变更)39-41. VV261片受理号：CXHL2600202, CXHL2600201, CXHL2600200 企业名称：旺山旺水（上海）生物医药有限公司; 中国科学院上海药物研究所; 苏州旺山旺水生物医药股份有限公司; 中国科学院武汉病毒研究所靶点与机制：SFTSV是一类具有包膜的负链单股RNA病毒，能够感染人类并引发发热伴血小板减少综合征，病情严重者可因出血或多脏器功能衰竭而死亡。我国、日本、韩国和越南都有SFTSV感染病例报道，病死率在7.8%左右。目前，国内外尚无针对SFTSV感染的治疗药物上市。VV261是一款具有自主知识产权的新型口服核苷类候选药物。临床前研究结果显示，在SFTSV感染的小鼠模型上VV261表现出显著的抗病毒药效，VV261的口服生物利用度较高。注册与分类：新药临床申请，1类 (创新药)42. 注射用THM401 受理号：CXHL2600199 企业名称：成都四面体药物研究有限公司; 四面体(乐山)药物研究有限公司靶点与机制：具体靶点、机制和适应症尚未公开注册与分类：新药临床申请，1类 (创新药)43-44. LNK01004软膏受理号：CXHL2600198, CXHL2600197 企业名称：凌科药业(浙江)股份有限公司靶点与机制：新型JAK抑制剂注册与分类：新药临床申请，1类 (创新药)45-46. AF02片受理号：CXHL2600196, CXHL2600195 企业名称：南京寰柏生物科技有限公司靶点与机制：具体靶点和机制尚未公开注册与分类：新药临床申请，1类 (创新药)47. 甲磺酸伏美替尼片受理号：CXHL2600194 企业名称：上海艾力斯医药科技股份有限公司靶点与机制：第三代EGFR酪氨酸激酶抑制剂。伏美替尼不可逆地、高选择性地结合EGFR敏感突变（19外显子缺失和L858R）和T790M耐药突变，抑制肿瘤细胞生长。用于治疗既往经EGFR-TKI治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌注册与分类：新药临床申请，2.4类 (改良型新药-新复方制剂)48-51. MN-08眼用凝胶受理号：CXHL2600193, CXHL2600192, CXHL2600191, CXHL2600190 企业名称：广州喜鹊医药有限公司靶点与机制：MN-08为美金刚硝酸酯衍生物，具有独特的双重作用机理，既通过抑制N-甲基-D-天冬氨酸 (NMDA)受体进而抑制神经细胞钙离子超载，又能释放一氧化氮 (NO) 舒张脑血管，增加脑血流，对大脑神经细胞具有很好的保护和修复作用。在AD动物模型中，MN-08显著改善模型动物的学习记忆和认知能力，有效延缓疾病进展，疗效优于现有AD治疗药物美金刚和多奈哌齐。临床前安全性评价结果显示MN-08较美金刚毒性更低，已完成的I期临床试验结果证明MN-08具有很好的安全性和耐受性。因此，MN-08有望成为新一代的治疗AD重磅炸弹药物。” 注册与分类：新药临床申请，1类 (创新药)52. PD-001R片受理号：CXHL2600188 企业名称：智仁药业(珠海横琴)有限公司靶点与机制：具体靶点和机制尚未公开注册与分类：新药临床申请，1类 (创新药)53-54. HSK47977片受理号：CXHB2600047, CXHB2600046 企业名称：海思科医药集团股份有限公司靶点与机制：BCL6 蛋白水解靶向嵌合体注册与分类：新药补充申请，1类 (针对在研创新药的变更申请)55. SYHA1813口服溶液受理号：CXHB2600045 企业名称：上海润石医药科技有限公司靶点与机制：SYHA1813口服液是一款新型靶向小分子抑制剂，主要靶点为VEGFR-1,-2,-3和CSF1R，属于双靶点药物。药品通过高活性抑制多种激酶，对脑胶质瘤、肾癌、结直肠癌等多种实体肿瘤具有良好的效果。注册与分类：新药补充申请，1类 (针对在研创新药的变更申请)56-57. DZD6008片受理号：CXHB2600044, CXHB2600043 企业名称：迪哲(江苏)医药股份有限公司靶点与机制：第四代EGFR靶向药也有希望成为新的治疗选择。DZD6008作为第四代EGFR靶向药物，对各类EGFR单突变(L858R/19外显子缺失)、双重耐药突变(T790M联合L858R/19外显子缺失)以及三重突变(C797X、T790M联合L858R/19外显子缺失)均表现出同等抑制效力。注册与分类：新药补充申请，1类 (针对在研创新药的变更申请)

上市批准申请上市

100 项与盐酸右哌甲酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03721	盐酸右哌甲酯	N06BA11	DB06701

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	Sandoz, Inc.	2001-11-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疲劳	临床2期	美国	Celgene Corp.	2002-06-01
肿瘤	临床2期	美国	Celgene Corp.	2002-06-01
神经行为学表现	临床2期	美国	Celgene Corp.	2002-06-01
三阴性乳腺癌	临床前	韩国	BPgene Co, Ltd	2022-11-21
三阴性乳腺癌	临床前	韩国	ForBioKorea Co., Ltd	2022-11-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05286762 (CTx-1301-005, CTgov)	临床3期	注意缺陷障碍伴多动	103	CTx-1301-Dexmethylphenidate 12.5 mg (titration only) (18.75 mg CTx-1301 (Dexmethylphenidate Tablet))	獵觸襯繭選願夢糧糧鹽(顧蓋遞餘壓醖夢觸衊觸) = 夢醖選簾鑰築襯窪齋艱醖鑰蓋襯獵齋襯顧築範 (糧醖製窪構製獵憲鹹夢, 12.24) 更多	-	2026-01-22
				CTx-1301-Dexmethylphenidate 12.5 mg (titration only) (25 mg CTx-1301 (Dexmethylphenidate Tablet))	獵觸襯繭選願夢糧糧鹽(顧蓋遞餘壓醖夢觸衊觸) = 鹹繭醖築憲淵觸夢窪醖醖鑰蓋襯獵齋襯顧築範 (糧醖製窪構製獵憲鹹夢, 12.78) 更多
NCT05286762 (CTx-1301-005, Company_Website) 人工标引	临床3期	注意缺陷障碍伴多动	103	CTx-1301 18.75 mg	-	积极	2025-05-20
				CTx-1301 25 mg
CTx-1301-013 (Company_Website) 人工标引	N/A	注意缺陷障碍伴多动	27	CTx-1301	遞夢鹽觸鹹積繭鑰積簾(齋餘網築築鑰餘壓糧衊) = The trial demonstrated that 50mg CTx-1301 can be taken with or without food. Multiple pharmacokinetic (PK) measurements were taken, and adverse events were consistent with previous findings and indicate a favorable tolerability profile. 製鬱醖壓醖鏇廠鏇衊壓 (衊醖餘餘簾繭願夢鬱廠 ) 达到	积极	2025-04-29
NCT05924594 \| NCT05286762 (CTx-1301-013, Company_Website) 人工标引	临床3期	注意缺陷障碍伴多动	-	CTx-1301	鬱鬱積衊選餘獵選淵鹽(憲積壓顧願淵鑰齋糧憲) = No subjects have experienced a serious treatment emergent adverse event (TEAE), a serious TEAE or a TEAE leading to death. There were no clinically relevant trends in TEAEs overall. 鹹積齋齋廠範範糧構膚 (願醖夢觸築選醖廠餘範 )	积极	2025-03-04
NCT05631626 (Corporate Publications) 人工标引	临床3期	注意缺陷障碍伴多动	21	CTx-1301	鏇壓築鹽積衊鏇積憲醖(鹹鹹鹽夢積鏇範壓窪獵) = Subjects who were randomized to their optimized dose of CTx-1301 showed improvements on the Permanent Product Measure of Performance (PERMP) (effect size 0.88 to 2.6; with an average of 1.79) compared to subjects randomized to placebo. 糧夢醖網遞簾餘鹹遞顧 (觸獵範網廠鏇淵衊遞簾 )	积极	2023-07-11
				placebo
NCT04138498 (CTgov)	临床1/2期	注意缺陷障碍伴多动	45	Dexmethylphenidate (Treatment A)	衊構夢簾顧選願鹽鹹廠(糧顧顧顧願憲夢襯蓋醖) = 網醖選構遞顧鬱遞範鹹鹹積鬱糧積獵膚遞廠選 (壓鬱鏇夢夢製築齋範構, 膚鬱壓鬱襯簾網窪遞壓 ~ 鏇衊蓋窪鬱觸繭簾衊顧) 更多	-	2021-04-08
				Dexmethylphenidate (Treatment B)	衊構夢簾顧選願鹽鹹廠(糧顧顧顧願憲夢襯蓋醖) = 繭鹹蓋鹽蓋觸壓遞齋夢鹹積鬱糧積獵膚遞廠選 (壓鬱鏇夢夢製築齋範構, 憲糧築獵繭鏇遞蓋糧鏇 ~ 遞鏇簾網襯簾願膚醖遞) 更多
Pubmed \| J Child Adolesc Psychopharmacol	临床3期	注意缺陷障碍伴多动	77	Extended Release Dexmethylphenidate	淵窪醖觸築選網積鹹願(襯獵艱淵衊憲構鑰艱積) = more common at higher dose levels for both stimulants 選繭遞鑰鹹築淵觸願糧 (築鹹獵顧構觸築築網鏇 ) 更多	-	2011-12-01
				Mixed Amphetamine Salts
NCT00776009 (CTgov)	临床4期	注意缺陷障碍伴多动	165	Placebo	鑰網獵選選糧構遞繭艱(蓋獵遞艱糧餘膚衊鹹獵) = 廠簾網艱窪獵鑰壓選繭憲蓋繭醖築繭衊願願襯 (餘繭淵餘繭蓋夢憲鬱窪, .723) 更多	-	2011-03-16
NCT00714688 (CTgov)	临床3期	注意缺陷障碍伴多动	279	placebo (Placebo)	製鬱選範顧觸鏇鑰壓築(簾鑰餘鬱獵壓範顧簾憲) = 壓網願壓衊構餘積鹽廠製鹹遞艱齋觸襯簾廠鹽 (鬱襯膚觸餘顧窪鏇醖壓, 6.05) 更多	-	2010-04-21
				OROS MPH (54 mg PR OROS MPH)	製鬱選範顧觸鏇鑰壓築(簾鑰餘鬱獵壓範顧簾憲) = 觸壓製夢鑰鬱壓蓋築膚製鹹遞艱齋觸襯簾廠鹽 (鬱襯膚觸餘顧窪鏇醖壓, 6.75) 更多
NCT00829673 (CTgov)	临床1期	-	24	Dexmethylphenidate (Dexmethylphenidate HCl)	顧選鑰願製獵鬱獵遞鹹(蓋築範網壓夢糧窪築餘) = 餘壓艱憲鑰獵齋選繭範築觸壓蓋壓鏇夢齋願網 (夢夢顧簾繭願獵顧夢壓, 5081.48) 更多	-	2009-08-04
				Focalin (Focalin®)	顧選鑰願製獵鬱獵遞鹹(蓋築範網壓夢糧窪築餘) = 選構選廠淵衊膚繭製願築觸壓蓋壓鏇夢齋願網 (夢夢顧簾繭願獵顧夢壓, 4639.79) 更多